"The structure of PGIM’s Private Shelf Facility was crucial in supporting our global operations and U.S. investments. We appreciated their tailored approach and understanding of our needs."
Karin de Jong, CFO, Fagron, NV
Fagron’s medical and therapeutical applications span from dermatology and pediatrics to primary care, acute care, and functional medicine. The Company holds the #1 market position in 8 markets in Europe, #1 market position in Latam for Brands & Essentials, and #2 market position in N. America for Brands & Essentials and Compounding Services.
PGIM’s relationship with Fagron began in 2013, when we were introduced through their sister company, Omega Pharma. In 2025, the Company desired financing for investments in North America. Fagron was drawn to PGIM’s Shelf facility due to its ability to diversify existing financing from banks, lengthen maturities, and obtain funding in USD.
In November 2025, Fagron established a $225 million PGIM Private Shelf Facility with an initial draw of $125 million. Fagron chose to work with us due to our relationship-oriented model and our ability to provide bespoke financing solutions.
We appreciated working with Fagron on this transaction, and we look forward to supporting the company for their future financing needs.
With an initial draw of
